Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SAVA Stock Summary
Top 10 Correlated ETFs
SAVA
In the News
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer's and Parkison's Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.
Exit Now! 3 Biotech Stocks to Sell in February 2024
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges.
3 small-cap biotechs with potential breakthroughs in 2024
There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.
Is There Any Hope for Cassava Sciences Stock?
Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to produce favorable data.
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies' performance relies heavily on drug approvals.
Portfolio Protection: 7 Risky Stocks to Drop Right Now
With investors moving back towards a “risk-on” stance in recent months, you may think that risky stocks could lead to outsized rewards this year. Yet while more favorable economic and market conditions could extend the current bull market (which started in October) well into 2024, an improving macro picture may not be enough for stocks that have large company-specific risks.
New SAVAW Warrants Are Trading After Cassava Sciences' Distribution
In the biotechnology sector, Cassava Sciences (NADSAQ: SAVA ) remains one of the top clinical-stage companies that investors are watching. Over the past one year, SAVA stock is down by less than 20% but up nearly 9% for the past six months.
Why Cassava Sciences Stock Zoomed 21% Higher This Week
The biotech has declared a fresh dividend. The payout is rather atypical -- it's in the form of common stock warrants.
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over management's decision to issue a warrant distribution to support the ongoing Phase 3 clinical development of oral simulfilam, a promising therapeutic for patients of Alzheimer's disease.
Why Cassava Sciences Stock Soared Today
The biotech significantly modified its board of directors. Two of those incoming directors have extensive experience in the healthcare field; the other comes from the security sphere.
SAVA Financial details
SAVA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.24 | -0.22 | -0.81 | -1.8 | -2.32 | |
Operating cash flow per share | -0.14 | -0.21 | -0.77 | -1.93 | -1.96 | |
Free cash flow per share | -0.15 | -0.21 | -1.33 | -2 | -1.97 | |
Cash per share | 1.33 | 3.58 | 5.92 | 5 | 2.89 | |
Book value per share | 1.27 | 3.53 | 6.44 | 5.66 | 3.28 | |
Tangible book value per share | 1.27 | 3.53 | 6.42 | 5.64 | 3.27 | |
Share holders equity per share | 1.27 | 3.53 | 6.44 | 5.66 | 3.28 | |
Interest debt per share | 0.01 | 0.01 | 0.01 | -0.09 | 0 | |
Market cap | 90.54M | 178.04M | 1.72B | 1.19B | 943.89M | |
Enterprise value | 67.55M | 84.82M | 1.49B | 986.69M | 822.75M | |
P/E ratio | -21.33 | -30.41 | -54.15 | -16.39 | -9.71 | |
Price to sales ratio | 0 | 0 | 0 | -659.76K | 0 | |
POCF ratio | -36.02 | -33.08 | -57.03 | -15.32 | -11.51 | |
PFCF ratio | -35.76 | -33.08 | -32.86 | -14.8 | -11.45 | |
P/B Ratio | 4.1 | 1.93 | 6.78 | 5.22 | 6.87 | |
PTB ratio | 4.1 | 1.93 | 6.78 | 5.22 | 6.87 | |
EV to sales | 0 | 0 | 0 | -548.16K | 0 | |
Enterprise value over EBITDA | -13.62 | -11.88 | -45.3 | -12.33 | -7.88 | |
EV to operating cash flow | -26.87 | -15.76 | -49.3 | -12.73 | -10.03 | |
EV to free cash flow | -26.68 | -15.76 | -28.41 | -12.3 | -9.98 | |
Earnings yield | -0.05 | -0.03 | -0.02 | -0.06 | -0.1 | |
Free cash flow yield | -0.03 | -0.03 | -0.03 | -0.07 | -0.09 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 4.64 | 13.06 | 7.1 | 2.51 | 1.16 | |
Current ratio | 16.83 | 50.4 | 19.51 | 29.91 | 9.13 | |
Interest coverage | 0 | 0 | 0 | 21.2 | 0 | |
Income quality | 0.54 | 0.85 | 0.93 | 1.02 | 0.84 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | -6.66K | 0 | |
Research and developement to revenue | 0 | 0 | 0 | -37.8K | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0.74 | 0.03 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 1.51K | 0 | |
Capex to depreciation | -0.31 | 0 | -41.6 | -2.08 | -0.27 | |
Stock based compensation to revenue | 0 | 0 | 0 | -1.15K | 0 | |
Graham number | 2.64 | 4.22 | 10.82 | 15.15 | 13.08 | |
ROIC | -0.2 | -0.06 | -0.13 | -0.33 | -0.77 | |
Return on tangible assets | -0.18 | -0.06 | -0.12 | -0.31 | -0.64 | |
Graham Net | 1.25 | 3.5 | 5.6 | 4.82 | 2.57 | |
Working capital | 21.96M | 92.13M | 231.95M | 204.16M | 115.44M | |
Tangible asset value | 22.1M | 92.2M | 252.84M | 226.92M | 137.29M | |
Net current asset value | 21.96M | 91.89M | 231.62M | 203.93M | 115.44M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 481K | |
Average payables | 373.5K | 682K | 4.02M | 5.57M | 7.3M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 2.85K | 961.03 | 4.87K | 1.13K | 2.52K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.13 | 0.38 | 0.07 | 0.32 | 0.14 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.19 | -0.06 | -0.13 | -0.32 | -0.71 | |
Capex per share | 0 | 0 | -0.56 | -0.07 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.06 | |
Net income per share | -0.43 | -0.52 | -0.63 | -0.61 | -0.5 | |
Operating cash flow per share | -0.52 | -0.32 | -0.48 | -0.63 | -0.53 | |
Free cash flow per share | -0.51 | -0.33 | -0.48 | -0.63 | -0.53 | |
Cash per share | 4.93 | 4.49 | 4.03 | 3.39 | 2.87 | |
Book value per share | 5.58 | 4.89 | 4.29 | 3.69 | 3.26 | |
Tangible book value per share | 5.57 | 4.88 | 4.28 | 3.69 | 3.25 | |
Share holders equity per share | 5.58 | 4.89 | 4.29 | 3.69 | 3.26 | |
Interest debt per share | -0.04 | -0.06 | 0 | 0 | 0.06 | |
Market cap | 1.2B | 1.01B | 1.02B | 698.91M | 949.65M | |
Enterprise value | 1B | 819.28M | 856.33M | 556.56M | 828.52M | |
P/E ratio | -17.37 | -11.63 | -9.71 | -6.81 | -11.35 | |
Price to sales ratio | -669.16K | 0 | 0 | 0 | 404.45 | |
POCF ratio | -56.5 | -75.95 | -51.43 | -26.34 | -42.55 | |
PFCF ratio | -57.4 | -73.96 | -51.45 | -26.32 | -42.48 | |
P/B Ratio | 5.29 | 4.93 | 5.71 | 4.51 | 6.91 | |
PTB ratio | 5.29 | 4.93 | 5.71 | 4.51 | 6.91 | |
EV to sales | -557.57K | 0 | 0 | 0 | 352.86 | |
Enterprise value over EBITDA | -47.94 | -30.9 | -29.76 | -19.96 | -36.93 | |
EV to operating cash flow | -47.07 | -61.81 | -42.98 | -20.98 | -37.13 | |
EV to free cash flow | -47.83 | -60.19 | -42.99 | -20.96 | -37.06 | |
Earnings yield | -0.01 | -0.02 | -0.03 | -0.04 | -0.02 | |
Free cash flow yield | -0.02 | -0.01 | -0.02 | -0.04 | -0.02 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 9.59 | 7.07 | 5.85 | 5.11 | 5.4 | |
Current ratio | 29.91 | 14.02 | 9.75 | 8.62 | 9.13 | |
Interest coverage | 11.61 | 10.22 | 0 | 0 | -8.66 | |
Income quality | 1.11 | 0.55 | 0.76 | 1.03 | 1.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | -1.83K | 0 | 0 | 0 | 1.73 | |
Research and developement to revenue | -9.81K | 0 | 0 | 0 | 7.98 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.02 | 0.03 | 0 | 0 | 0 | |
Capex to revenue | -186.11 | 0 | 0 | 0 | -0.02 | |
Capex to depreciation | 0.86 | -0.91 | 0.02 | -0.06 | -0.12 | |
Stock based compensation to revenue | -342.22 | 0 | 0 | 0 | 0.91 | |
Graham number | 7.31 | 7.55 | 7.81 | 7.12 | 6.03 | |
ROIC | -0.08 | -0.12 | -0.14 | -0.16 | -0.23 | |
Return on tangible assets | -0.07 | -0.1 | -0.13 | -0.15 | -0.14 | |
Graham Net | 4.75 | 4.15 | 3.61 | 2.98 | 2.55 | |
Working capital | 204.16M | 181.09M | 156.64M | 132.77M | 115.44M | |
Tangible asset value | 226.92M | 203.5M | 178.97M | 154.85M | 137.29M | |
Net current asset value | 203.93M | 180.89M | 156.64M | 132.77M | 115.44M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 664K | 1.31M | 1.12M | |
Average payables | 3.78M | 6.13M | 9.29M | 9.92M | 10.03M | |
Average inventory | 0 | 0 | -664K | -1.31M | -642.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 36.87 | |
Days payables outstanding | 929.38 | 1.9K | 2.38K | 2.18K | 2.67K | |
Days of inventory on hand | 0 | 0 | -305.68 | -295.03 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 2.44 | |
Payables turnover | 0.1 | 0.05 | 0.04 | 0.04 | 0.03 | |
Inventory turnover | 0 | 0 | -0.29 | -0.31 | 0 | |
ROE | -0.08 | -0.11 | -0.15 | -0.17 | -0.15 | |
Capex per share | 0.01 | -0.01 | 0 | 0 | 0 |
SAVA Frequently Asked Questions
What is Cassava Sciences, Inc. stock symbol ?
Cassava Sciences, Inc. is a US stock , located in Austin of Tx and trading under the symbol SAVA
What is Cassava Sciences, Inc. stock quote today ?
Cassava Sciences, Inc. stock price is $20.1332 today.
Is Cassava Sciences, Inc. stock public?
Yes, Cassava Sciences, Inc. is a publicly traded company.